Gene Research
sFlt-1 gene therapy halts pathological neovascularization in animal eyes
Published in Gene Therapy Weekly, December 1st, 2005
"Vascular endothelial growth factor (VEGF) is one of the major mediators of retinal ischemia-associated neovascularization. We have shown here that adeno-associated virus (AAV)-mediated expression of sFlt-1, a soluble form of the Flt-1 VEGF receptor, was maintained for up to 8 and 17 months postinjection in mice and in monkeys, respectively," scientists writing in the journal Molecular Therapy report.
"The expression of sFlt-1 was associated with the long-term (8 months) regression of neovascular vessels in 85% of trVEGF029 eyes. In addition, it resulted in the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-12-01)
More Articles from Gene Therapy Weekly
- Gene Research
Vascular endothelial growth factor gene change enhances safety of gene therapy - Macular Degeneration
RS1 gene therapy aids X-linked juvenile retinoschisis murine models - Peripheral Vascular Disease
Gene therapy promotes arteriogenic and angiogenic responses in ischemic limbs - Antibacterial Agents
REP8839 antibacterial activity is due to inhibition of a methionyl-tRNA synthetase - Atherogenesis
Human paraoxonase-3 can be cloned and highly expressed - Atherosclerosis
Researchers' findings advance atherosclerosis research - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
